MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revive Therapeutics Ltd (OP:RVVTF)

0.0210 -0.0009 (-4.11%)
Streaming Delayed Price Updated: 3:54 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 198,794
Open 0.0215
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0219
Today's Range 0.0203 - 0.0245
52wk Range 0.0060 - 0.0585
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Via ACCESS Newswire
News headline image
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
From Revive Therapeutics Ltd.
Via GlobeNewswire

Performance

YTD
+128.3%
+128.3%
1 Month
-26.6%
-26.6%
3 Month
+162.5%
+162.5%
6 Month
+144.2%
+144.2%
1 Year
+9.9%
+9.9%

More News

Read More
News headline image
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Extension of Proposed Private Placement
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Advances with Next-Generation Bucillamine Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Proposed Shares for Debt Transaction
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Results of Annual Shareholder Meeting
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis
Via Newsfile
News headline image
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves ↗
Via Benzinga
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Revive Therapeutics Ltd publicly traded?
Yes, Revive Therapeutics Ltd is publicly traded.
What exchange does Revive Therapeutics Ltd trade on?
Revive Therapeutics Ltd trades on the OTC Traded
What is the ticker symbol for Revive Therapeutics Ltd?
The ticker symbol for Revive Therapeutics Ltd is RVVTF on the OTC Traded
What is the current price of Revive Therapeutics Ltd?
The current price of Revive Therapeutics Ltd is 0.0210
When was Revive Therapeutics Ltd last traded?
The last trade of Revive Therapeutics Ltd was at 05/11/26 03:54 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story